Lupin launches Azilsartan generic in US with 180-day exclusivity
First-to-file Azilsartan Medoxomil tablets hit the US market, but the $53.5M reference product adds less than 0.3% to Lupin's annual revenue.
— 7 earlier stories on Lupin Ltd. →What's new
- Lupin launched the first-to-file generic of Azilsartan Medoxomil in the US.
- The product is eligible for 180-day generic exclusivity as the first filer.
- Reference product Edarbi had estimated US sales of $53.5M (₹44 crore).
Why this matters
The exclusivity period offers higher margins, but the absolute market size is a rounding error for Lupin — less than 0.3% of its ₹19,000+ crore annual revenue. The launch is routine portfolio filler, not a needle mover.
What we're watching
- Whether Lupin lands more first-to-file opportunities in the US pipeline.
- How the 180-day exclusivity period's margins translate into quarterly contribution.
The full read
Lupin has launched the first-to-file generic of Azilsartan Medoxomil in the US, bagging 180 days of generic exclusivity. The reference product Edarbi had estimated annual US sales of $53.5 million (roughly ₹44 crore). For a company with over ₹19,000 crore in annual revenue, that is less than 0.3% of turnover. It is tiny. Exclusivity will lift margins for a quarter or two, but the absolute sum is too small to move the needle. This is routine portfolio maintenance, not a catalyst. The scoring reflects that.
Questions answered
- What is Azilsartan Medoxomil and why does exclusivity matter?
- Azilsartan Medoxomil is a hypertension drug, brand name Edarbi. As first filer, Lupin gets 180 days of generic exclusivity in the US, meaning no other generics can compete during that window, which typically allows for higher margins.
- How significant is this launch for Lupin's financials?
- It's minor. The reference product's entire US market is about ₹44 crore annually, which is less than 0.3% of Lupin's annual revenue. Even with exclusivity margins, it won't materially affect earnings.
- What is Lupin's current size and valuation?
- Lupin has a market cap above ₹1 lakh crore, trailing revenue growth of 31.9%, and PAT growth of 87.7%. In its latest reported quarter (Mar 2026), it posted sales of ₹7,475 crore and net profit of ₹1,469 crore.
- Does this launch signal a shift in Lupin's US strategy?
- No. It's a routine addition to the US generic portfolio, similar in scale to prior approvals that have a negligible impact on the investment thesis. Lupin remains focused on larger opportunities like interchangeable biosimilars.
- How does this compare to Lupin's recent US approvals?
- In June 2026, Lupin won approval for a generic Halaven (market size $43.7M) and launched a biosimilar for Lucentis. The Azilsartan launch is smaller and less significant than both.
Lupin Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on LUPIN →- 17 Jun 2026 · 5:09 PM IST Lupin launches Azilsartan generic in US with 180-day exclusivity
- 5d ago Lupin's Somerset plant gets FDA's cleanest inspection verdict
- 5d ago Lupin wins wider European label for rare-disease drug NaMuscla
- 28d ago Lupin takes Luforbec to Spain, its third European market
- 31d ago Lupin lands sole US interchangeable biosimilar for Roche's Lucentis